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Long-term oxygen therapy (LTOT) has been shown to improve survival in hypoxaemic patients with chronic 
obstructive pulmonary disease (COPD). This has resulted in recommending the prescription of oxygen for at least 
15 h day- ’ in most European countries. 
In order to examine the prescription and usage of LTOT and to assess the adherence to international 
recommendations for its prescription, a survey was set up in a random sample of clients of the largest oxygen 
company in the Netherlands. After patients had been visited for an interview, additional postal surveys were sent to 
the physician who had prescribed LTOT and to the oxygen company. 
For 175 COPD patients the mean oxygen prescription and mean oxygen usage were 15.6 f 5.8 and 14.1 & 6.8 h 
day - ‘, respectively. In 62 patients (35%) oxygen was prescribed < 15 h day - ‘, more often by non-chest physicians 
than by chest physicians (P<O.OOOl), and 91 patients (52%) used oxygen < 15 h day- ‘. Of 113 patients with a 
prescription 2 15 h day - ‘, 39 (35%) used oxygen < 15 h day - ’ and 74 for 2 15 h day - ‘. The latter were prescribed 
oxygen for more h day - i , had been longer on LTOT, had a higher resting flow rate, were prescribed a concentrator, 
employed portable cylinders and used oxygen in public significantly more often than the former, 
We conclude that in a selected group of LTOT patients with COPD both oxygen prescription and usage were 
often inadequate, particularly if LTOT was prescribed by non-chest physicians. 
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Introduction 
Long-term oxygen therapy (LTOT) has been shown to 
improve survival in hypoxaemic patients with chronic 
obstructive pulmonary disease (COPD) (1,2). As a result, 
the American Thoracic Society and the European 
Respiratory Society have issued recommendations for the 
prescription of LTOT and in many countries prescription 
guidelines have been formulated, which usually recommend 
prescribing oxygen for at least 15 h day - ’ (3-5). 
In 1992 some 6000 patients in the Netherlands were 
prescribed LTOT and the number of LTOT patients per 
100 000 inhabitants was one of the highest in Europe (6). 
Nevertheless, national prescription guidelines have not been 
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issued yet. In the same year the impression was created, by 
both patients and oxygen companies, that the therapy was 
often prescribed improperly. In addition, little was known 
about oxygen usage and data on compliance were lacking. 
On the basis of the literature compliance to therapy 
was expected to be poor (7-11). Finally, factors affecting 
compliance had not yet been extensively clarified. 
The aims of this study were, therefore, to examine the 
prescription and usage of LTOT in COPD patients, to 
assess patient compliance to the therapy and to analyse 
the adherence to international recommendations for the 
prescription of LTOT. 
Methods 
STUDY DESIGN 
The patients of this study took party in a survey which was 
set up in a sample of 2523 clients of the largest oxygen 
company in the Netherlands (Hoek Loos Co., Schiedam, 
the Netherlands) (12). After they had been coded by 
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number, 138 1 patients were randomly chosen by computer. 
Subsequently, patients were selected if they were at least 
18 years, had a telephone connection and had possessed 
oxygen equipment at home for at least 6 months. 
Of the 895 patients who fulfilled these criteria, 341 
(38%) refused to participate and 26 (3%) could not 
take part for reasons of severe illness or early death. A 
total of 528 patients, including 369 COPD patients, were 
visited at home for an interview by a medical student. 
Prior to the visit, the students had been trained in formu- 
lating the questions of a questionnaire and they had been 
instructed that all questions had to be answered by the 
patients themselves. At the end of the interview each 
patient was asked for informed consent to send additional 
postal surveys both to the physician who had prescribed 
LTOT and to the oxygen company. This study was 
approved by the Medical Ethics Committee of our 
hospital. 
DEFINITIONS AND MEASUREMENTS 
PrePhy is the daily length of the treatment prescribed, 
according to the physician. In the assessment of the extent 
to which physicians followed the international recommen- 
dations for LTOT prescription, a daily oxygen prescrip- 
tion 215h day-’ was defined as ‘adequate’, while a 
prescription < 15 h day - i was considered as ‘inadequate’ 
(3,4X 
As oxygen usage was not actually measured and reliable 
data on this matter could not be obtained from the oxygen 
company, daily oxygen usage was assumed to be as stated 
by the patients (UsaPat). The one and only controlled 
trial comparing oxygen with no oxygen in severe chronic 
hypoxaemia showed that the minimum time for clinical 
benefit was 15 h day - r (2). For this reason, patients using 
LTOT for a minimum of 15 h day - ’ were defined as 
‘effective’ users of treatment, while patients using it for 
c15h day-’ were considered to be ‘ineffective’ users. 
Patients who were prescribed oxygen for 2 15 h day - ’ and 
who also used it for this number of hours were classified 
as ‘compliant’. Those with a prescription of L 15 h day - ‘, 
but who used oxygen for < 15 h day - ’ were classed as 
‘non-compliant’. 
DATA ANALYSIS 
Data analysis was performed and descriptive statistics 
obtained using the SPSS/PC+program (SPSS Inc., 
Chicago, U.S.A.). Continuous values are reported as 
mean 5 SD. Subgroups were compared by Mann-Whitney 
U-tests for continuous variables, and by Fisher’s exact tests 
in contingency tables for categorical variables. Linear 
regression analysis was applied to relate UsaPat to PrePhy. 
The physicians’ answers were supposed to represent the 
prescription correctly and were, therefore, regarded as the 
predicting variable. Two-sided tests were employed 
throughout and a P-value of ~0.05 was considered 
significant. 
Results 
For 175 COPD patients data on both oxygen prescription 
and usage were available. Table 1 lists their charac- 
teristics and those of the 194 COPD patients who were 
excluded because their doctors did not reply. No statisti- 
cally significant differences were found between both 
patient groups. 
OXYGEN PRESCRIPTION 
Apart from the fact that the number of daily hours of 
oxygen prescribed was unknown to 52 patients (30%), 
patients and physicians held different views on the daily 
length prescribed (Table 2). A prescription 2 15 h day - i 
was not related to age or mobility of the patients, the 
number of follow-up visits or duration of LTOT. The 
median flow rate prescribed was 1 .O 1 min - ‘, both at rest, 
during exercise and sleep. Sixty-three patients (36%) stated 
that LTOT had mainly been prescribed for dyspnoea. 
In 149 patients (85%) LTOT had been prescribed by a 
chest physician, in 17 (10%) by a general practitioner (GP) 
and in nine (5%) by an internist. GPs wrote prescriptions 
more often than chest physicians on the basis of ‘if neces- 
sary’ (P<O.OOl). The latter prescribed oxygen more often 
>15hday-’ than non-chest physicians (BO.001). 
Usually the decision between an oxygen concentrator and 
cylinders was left to the oxygen company. Liquid oxygen, 
however, was only installed if prescribed by a physician. 
OXYGEN USAGE 
More than half of the patients used oxygen ~15 h day- ’ 
and 10 applied it only ‘if necessary’ (Table 2). For 175 
patients the mean UsaPat and mean PrePhy were 14.1 & 
6.8 and 15.6 f 5.8 h day- ‘, respectively, with the follow- 
ing relationship: UsaPat = 3.9 + 0.66 * PrePhy; P<O.OOl for 
H,,P=l (Fig. 1). Although UsaPat increased with PrePhy, 
increasing the length prescribed did not guarantee a usage 
of 2 15 h day-‘. As compared to patients using ~15 h 
day-‘, those using oxygen 2 15 h day- i had been pre- 
scribed LTOT more often L 15 h day - ’ than c 15 h day - ’ 
(P<O.OOl). This was done more frequently by chest 
physicians than by non-chest physicians (P=O.O06), and 
mainly for hypoxaemia rather than dyspnoea (P=O.O097). 
In addition, patients who used oxygen 2 15 h day - ’ were 
more often women (P=O.O19), used a concentrator more 
frequently (P<O.OOl), had more complaints due to LTOT 
(P=O.O04) and had been prescribed a higher flow rate at 
rest (BO.001) than the patients who used it < 15 h day- ‘. 
UsaPat-PrePhy was negative in 83 (47%) and positive in 47 
patients (27%), and decreased with PrePhy. The number of 
patients who used fewer daily hours than prescribed was 
larger if oxygen was prescribed L 15 h day - ’ than if it was 
prescribed < 15 h day - ’ (P=O.O023), and increased with 
PrePhy (Fig. 2). 
Of the 113 patients with an oxygen prescription of 2 15 h 
day - ‘, 39 patients (35%) used oxygen < 15 h day - I and 74 
for >15hday-‘. The latter differed from the former with 
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TABLE 1. Demographic and clinical data for the COPD patients who were included and for those 
excluded because their physicians did not reply* 
Included Excluded 
(n= 175) (n= 194) 
Sex ratio (M:F) 
Age (years) 
Duration of LTOT (years) 
Oxygen prescription (h day - ‘) 
Oxygen usage (h day - ‘) 
Overall compliance (h day- ‘) 
Visits to physician (n yr - ‘) 
Prescribed by chest physician 
Prescribed by general practitioner 
Ex-smokers 
Smokers 
Living alone 
Needing help from other people 
Oxygen source 
Cylinders 
Concentrator 
Liquid 
Combination 
Receiving portable cylinders 
Using portable cylinders 2 1 week - i 
Delivery device 
Nasal prongs 
Nasopharyngeal catheter 
Cuffed nasal catheter 
Transtracheal microcatheter 
Oxygen mask 
Other 
Complaints (61% had >one complaint) 
Restricted autonomy 
Duration of therapy 
Shame 
Oxygen source 
Delivery device 
12550 
70.1 f 7.7 
3.3 f 3.2 
16.8 f 5.8 
14.1 f 6.8 
- 0.5 f 2.6 
4.5 f 4.7 
149 (85) 
17 (10) 
127 (73) 
28 (16) 
36 (21) 
111 (63) 
144 (82) 
22 (13) 
7 (4) 
2 (1) 
112 (64) 
35 (31) 
157 (90) 
9 (5) 
4 (2) 
2 (1) 
1 (1) 
2 (1) 
90 (51) 
18 (10) 
66 (38) 
81 (46) 
81 (46) 
136:58 
69.0 zt 9.7 
3.9 f 3.5 
16.5 f 7.3 
12.8 zk 8.0 
- 1.0*4.4 
4.3 * 4.5 
166 (86) 
21 (11) 
135 (70) 
35 (18) 
50 (26) 
126 (65) 
157 (81) 
25 (13) 
9 (5) 
3 (2) 
114 (59) 
39 (34) 
166 (86) 
17 (9) 
5 (3) 
3 (2) 
3 (2) 
105 (54) 
14 (7) 
70 (36) 
74 (38) 
77 (40) 
*All data were provided by the patients. Values are presented either as mean f SD or as number of 
patients with percentage in parentheses. None of the differences were statistically significant, 
respect to the oxygen prescription and usage, duration of 
LTOT, resting flow rate, and concentrator and portable 
cylinder use (Table 3). There were, however, no differ- 
ences in age, sex, reason for starting LTOT, prescribing 
physician, the number of smokers, complaints due to the 
treatment, reduction of dyspnoea following the start of 
LTOT, living conditions or in the number of follow-up 
visits between compliant and non-compliant patients, all of 
whom had an oxygen prescription of 2 15 h day - ‘. 
Discussion 
This study demonstrates that in a selected group of LTOT 
patients with COPD more than one-third of the physicians 
who prescribed LTOT did not adhere to international 
recommendations, more than half of the patients used 
oxygen ineffectively, and almost half of the patients used it 
for fewer daily hours than prescribed. 
Inadequate prescription was probably caused by the 
still-existing misconception that the therapy is aimed at 
the symptomatic relief of breathlessness, and also by 
non-adherence to the international recommendations 
because physicians were apparently not aware of them. 
The duration of the treatment prescribed was inadequate, 
particularly if it was done by non-chest physicians. 
This finding is consistent with several other studies 
(10,13,14). In some European countries the prescription 
of LTOT is, therefore, restricted to chest physicians 
(15,16). 
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TABLE 2. Oxygen prescription (Pre) and oxygen usage (Usa) 
according to physicians (Phy) and patients (Pat) (n= 175)* 
PrePhy PrePat UsaPat 
Period 
If necessary only 
At night only 
Continuously 
Miscellaneous 
Unknown 
Daily hours 
215 
<I5 
Unknown 
2 (1) 23 (13) 10 (6) 
31 (18) 46 (26) 48 (27) 
46 (26) 56 (32) 55 (31) 
44 (25) 31 (18) 62 (35) 
52 (30) 19 (11) 
113 (65) 91 (52) 84 (48) 
62 (35) 32 (18) 91 (52) 
52 (30) 
*Values are presented as numbers of patients with percent- 
ages in parentheses. 
I 
0 3 6 9 12 15 18 21 24 
Prescription (h day-‘) 
FIG. 1. Individual and average relationship between daily 
oxygen usage, according to the patient, and daily oxygen 
prescription, as given by the physician, in 175 COPD 
patients (r=0.56; P<O.OOl). Individual data points are 
shown. Solid lines represent the mean f SD. The horizon- 
tal dashed line distinguishes effective ( 2 15 h day- i) from 
ineffective (< 15 h day - ‘) users; the vertical dashed line 
distinguishes adequate (2 15 h day - ‘) from inadequate 
(C 15 h day - ‘) prescriptions. 
The prescription was also inadequate with regard to 
the oxygen flow rates. Most patients were prescribed 
l.Olmin-‘? irrespective of their activity level. Such a flow 
rate is quite low and probably not adequate even at rest 
(17). To keep them well oxygenated, patients frequently 
need extra oxygen during sleep and exercise (18). Hence, 
titration of the oxygen flow rate during sleep and exercise is 
recommended to prevent serious hypoxaemia (3,4). 
Furthermore, both the content of the prescription and 
the way in which it was given to the patients were frequently 
inadequate, as 30% of the patients was unaware of the 
number of daily hours prescribed, and patients and their 
physicians held different opinions on the prescribed daily 
60, 
<8 
Prescribed daily hours 
FIG. 2. Difference between the used (U) and prescribed 
(P) daily hours of oxygen therapy per patient, in relation 
to the prescribed duration of treatment in 175 patients 
(Mantel-Heanszel test: P=O.O18). The number of patients 
is given above each bar. (0, U<P; W, U=P; El, U>P.) 
length of the treatment. Physicians should make every effort 
to give their patients adequate instructions, preferably 
orally as well as in writing. 
It is very plausible that ineffective oxygen usage was 
caused by the trouble induced by the treatment, like 
restricted autonomy and complaints due to the oxygen 
equipment (12). Due to the local density and accessibility of 
patients and because of the reimbursement policies in the 
Netherlands the oxygen companies supplied most patients 
with oxygen cylinders until recently. 
In addition, ineffective usage may also have been caused 
by inadequate prescription. Several studies, however, have 
shown a comparable oxygen usage, even when patients had 
been prescribed oxygen for 2 15 h day- ’ (11,19,20). In 
accordance with other studies, our study showed that 
effective oxygen usage was positively related to disease 
severity, LTOT duration, concentrator use, oxygen usage 
during indoor movements and to the resting oxygen flow 
rate, all of which may be explained by progressive hypox- 
aemia (9,19). Oxygen usage also increased with the daily 
hours prescribed. Although important, prescribing enough 
daily hours was no guarantee for effective usage since, even 
when oxygen was prescribed continuously, seven out of 35 
patients still followed this advice for < 15 h day - i. Further- 
more, oxygen usage improved when LTOT had been pre- 
scribed by chest physicians. The latter is in keeping with a 
study in which more than 90% of the 560 patients, who were 
prescribed oxygen for a mean of 19 h day- i by chest 
physicians only, reported using oxygen for 2 15 h day - ’ 
(21). The present findings demonstrate that non-compliance 
is a serious problem in COPD patients with LTOT. Poor 
compliance may have been due to a relatively good clinical 
condition, insufficient motivation and encouragement of 
patients, and to inconvenience induced by the treatment. 
Oxygen usage is a problem for many patients, particularly 
when moving in and around the house, going out and 
meeting other people. The latter is probably related to the 
weight of the portable cylinders and to stigmatization 
caused by the nasal cannulae. Portable liquid oxygen may 
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TABLE 3. Differences between compliant patients (n=74) using oxygen 2 15 h day - i, and non- 
compliant patients (n = 39) using oxygen < 15 h day - ‘, all of whom had been prescribed oxygen for 
215 h day-‘* 
Compliant Non-compliant P-value 
Prescription according to physicians (h day- i) 19.5 & 3.8 17.9 & 3.2 0.018 
Prescription according to patients (h day - ‘) 19.9 f 4.0 13.7 & 3.6 <O*OOl 
Usage according to patients (h day - ‘) 20.1 f 3.9 9.9 f 3.6 <O.OOl 
Duration of LTOT (years) 3.4 f 2.8 2.4 f 2.1 0.048 
Resting flow rate (1 min - ‘) 1.2 f 0.6 0.7 * 0.7 0.002 
Urged to use more (h day- *) l/74 (1) 4139 (10) 0.047 
Concentrator use 16/74 (22) 2139 (5) 0.013 
Use of portable cylinders 48/59 (81) 13124 (54) 0.01 
Use in public 59/70 (84) 19/31 (61) 0.011 
Use during transfers at home 50/73 (69) 5139 (13) <0~0001 
Use when being visited 66/74 (89) 6139 (15) <0~0001 
Use when visiting 39159 (66) 2133 (6) <0~0001 
*Values are given either as mean f SD or numbers of patients with percentages in parentheses. 
facilitate oxygen usage during activities and thereby 
increase daily oxygen usage (22,23). Given the negative 
influence of shame on compliance, the latter may be 
improved by transtracheal oxygen therapy in selected 
patients (24). 
The fact that only 10% of the non-compliant patients 
were urged to use oxygen for more hours a day casts doubt 
on the effectiveness of the follow-up visits. Encouragement 
and close supervision of patients, as well as assistance of 
specially trained nurses forming part of a home care 
programme are recommended to improve compliance 
(20,25-27). 
Being part of a survey which was set up in a random 
sample of LTOT patients, this study has several limitations. 
Similar to most other studies in this field, it was retrospec- 
tive. Consequently, selection bias may have occurred. Only 
59% of the 895 selected patients were interviewed. In 
addition, 194 (53%) of the 369 COPD patients had to be 
excluded because of a lack of doctors’ postal reply. 
Although these patients did not differ from the participants, 
their physicians prescriptions might have. It was not poss- 
ible to ascertain whether the latter were less interested in the 
field, and thus probably less informed and not adhering to 
prescription guidelines, or well informed but simply too 
busy to respond. Furthermore, the information on each 
patient was limited. Data on lung function, blood gases and 
medication were, for example, absent. Finally, the oxygen 
usage was not actually measured and reliable data on this 
matter could not be obtained from the oxygen company. As 
it is well known that patients tend to overestimate their 
oxygen consumption, oxygen usage and the number of 
compliant patients in our population are likely to be even 
less than reported (10,19). Nevertheless, the outcome of this 
study is considered to be representative of the situation in 
the Netherlands. 
We conclude that in a selected group of LTOT patients 
with COPD both oxygen prescription and usage were 
inadequate, particularly if this treatment was initiated by 
non-chest physicians. We recommend that LTOT should be 
prescribed by chest physicians, who should educate and 
encourage their patients in an attempt to gain effective use 
of oxygen therapy. To improve compliance, the assistance 
of specially trained nurses forming part of a home-care 
programme may be helpful and the oxygen equipment 
should become more acceptable to patients. 
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